{"id":"W2319946384","doi":"10.1016/j.jaci.2016.02.027","title":"Efficacy and safety of multiple doses of QGE031 (ligelizumab) versus omalizumab and placebo in inhibiting allergen-induced early asthmatic responses","year":2016,"lang":"en","type":"article","venue":"Journal of Allergy and Clinical Immunology","topic":"Asthma and respiratory diseases","field":"Medicine","cited_by":135,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of British Columbia; University of Alberta; University of Saskatchewan; University of Calgary; Institut universitaire de cardiologie et de pneumologie de Québec; McMaster University","funders":"Canadian Institutes of Health Research; Novartis Pharma; Boston Scientific Corporation; Sanofi; AstraZeneca; GlaxoSmithKline; Amgen","keywords":"Omalizumab; Medicine; Placebo; Immunoglobulin E; Asthma; Allergen; Cohort; Immunology; Allergy; Dosing; Gastroenterology; Internal medicine; Antibody; Pathology","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001397451,0.0009110781,0.004114925,0.0004167096,0.0003292095,0.0008035508,0.0008890179,0.001652724,0.002521091],"category_scores_gemma":[0.001135225,0.0005452452,0.00139066,0.0002821131,0.0008526305,0.001280823,0.0003211538,0.002448025,0.0006158542],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000590584,"about_ca_system_score_gemma":0.0006787776,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005592601,"about_ca_topic_score_gemma":0.000797889,"domain_scores_codex":[0.9992458,0.0003072579,0.00007013446,0.0001243555,0.00007786334,0.0001745541],"domain_scores_gemma":[0.9993609,0.000184683,0.0001301494,0.00005791224,0.00002952629,0.0002369267],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9179403,0.008117815,0.0007044682,0.0002609766,0.0005249131,0.00006729038,0.0000349597,0.0006506613,0.02624843,0.00009861188,0.0002743965,0.0450772],"study_design_scores_gemma":[0.4856802,0.4624104,0.02386139,0.0001026499,0.001920829,0.0003875296,0.00009073214,0.003139572,0.0205218,0.0003739092,0.001420728,0.00009040798],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.993329,0.00494718,0.0002804134,0.0002637345,0.0001678068,0.0001556152,0.0001814405,0.00006556573,0.0006092908],"genre_scores_gemma":[0.9972791,0.001060294,0.0004406428,0.0001433659,0.0001701662,0.0001761656,0.0001217033,0.000009362954,0.0005992725],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004114925,"threshold_uncertainty_score":0.008433938,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03612521874947035,"score_gpt":0.3325467524097778,"score_spread":0.2964215336603075,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}